Related Experiment Videos
Technology evaluation: gene therapy (mesothelioma), NCI
1Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. banerjed@mskcc.org
Current Opinion in Molecular Therapeutics
|November 21, 2001
Summary
This phase I clinical trial explores gene therapy for malignant mesothelioma using recombinant adenovirus with the HSV-tk gene and ganciclovir. The study aims to assess the safety and efficacy of this novel cancer treatment approach.
Area of Science:
- Oncology
- Gene Therapy
- Clinical Trials
Background:
- Malignant mesothelioma is a rare and aggressive cancer.
- Current treatment options for malignant mesothelioma have limited efficacy.
- Gene therapy offers a novel approach to target and destroy cancer cells.
Purpose of the Study:
- To evaluate the safety and feasibility of gene therapy for malignant mesothelioma.
- To assess the efficacy of recombinant adenovirus-mediated gene transfer and ganciclovir treatment.
- To determine the maximum tolerated dose of the investigational therapy.
Main Methods:
- A phase I clinical trial was conducted.
- Patients received administration of recombinant adenovirus containing the HSV-tk gene.
- Subsequent tumor kill was induced by ganciclovir.
Main Results:
- Twenty-one patients with malignant mesothelioma were enrolled.
- The study is ongoing, and results are pending.
- Preliminary safety data is being collected.
Conclusions:
- Gene therapy represents a promising avenue for malignant mesothelioma treatment.
- Further research is needed to confirm the efficacy and long-term outcomes.
- This trial will provide crucial data for future therapeutic strategies.